Kolexia
Ambrosetti Damien Anatomie et cytologie
Ambrosetti Damien
Anatomie et cytologie
Hôpital Pasteur
Nice, France
160 Activités
1.4 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Tumeurs du rein Carcinome épidermoïde Métastase tumorale Tumeurs cutanées Carcinome épidermoïde de la tête et du cou Tumeurs de la prostate Tumeurs de la tête et du cou

Collaborateurs

Voir plus
Michiels Jean Francois
Michiels Jean Francois
Hôpital Pasteur, Nice, France
Durand Matthieu
Durand Matthieu
Hôpital Pasteur, Nice, France
Pedeutour Florence
Pedeutour Florence
Centre Antoine Lacassagne, Nice, France
Bernhard Jean-Christophe
Bernhard Jean-Christophe
Hôpital Pellegrin, Bordeaux, France

Industries

Voir plus
AstraZeneca
11 collaboration(s)
Dernière en 2022
MSD
2 collaboration(s)
Dernière en 2021
BMS
2 collaboration(s)
Dernière en 2023
Merck-Serono
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation: A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a Kras Mutation
Essai Clinique (Cardiff Oncology)   29 février 2024
SALON DU LYCÉEN ET DE L'ÉTUDIANT
Youtube @ UFR médecine   22 novembre 2023
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Essai Clinique (Cardiff Oncology)   31 octobre 2023
Improving CNNs classification with pathologist-based expertise: the renal cell carcinoma case study.
Scientific reports   23 septembre 2023
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.
Molecular oncology   18 avril 2023
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2): A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy
Essai Clinique (Boehringer Ingelheim)   06 février 2023
Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15).
BJU international   01 février 2023
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): A Phase 1b/2 Study of PCM-075 (Onvansertib) in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)
Essai Clinique (Cardiff Oncology)   31 janvier 2023
Onychomatricoma: a clinicopathological, immunohistochemical, and molecular study of 10 cases highlighting recurrent RB1 deletion and the potential diagnostic value of LEF-1.
Histopathology   24 janvier 2023
Oncocytoma on renal mass biopsy: is it still the same histology when surgery is performed? Results from UroCCR-104 study.
World journal of urology   12 janvier 2023